BOOK REVIEW

Modulators of Glutamatergic Signaling as Potential Treatments for Neuropsychiatric Disorders
Editors: Zoran M. Pavlovic, M.D.

The book “Modulators of glutamatergic signaling as potential treatments of neuropsychiatric disorders” edited by Zoran Pavlovic and published by Nova Science comes at a critical moment when drug development for psychiatric and neurological disorders is searching for new targets. Glutamate is widely present in the brain and is involved in normal nervous system functioning and neuroprotection. Over the past years the glutamatergic system has received increased attention due to its role in the pathology of several conditions related to cognition, mood, and neurodegeneration. Currently, an important number of compounds are in clinical development targeting the various receptors and transporters that play a part in glutamatergic signaling.

Experts from academia and the pharmaceutical industry have contributed chapters on ADHD, Alzheimer’s, migraine, aggression, schizophrenia, OCD and addiction, each containing a description of the disorder and providing the historical perspective in relation to glutamate. Current treatments targeting the glutamate system and future perspectives for new compounds are discussed for the various indications. The book provides a solid and succinct overview to a broad audience and will be of interest to students of medicine or pharmacology, clinical pharmacologists, psychiatrists and neurologists concerned with pharmacotherapy and drug developers in the pharmaceutical industry involved with CNS compounds.

Some areas like depression, multiple sclerosis, ALS, epilepsy, stroke or traumatic brain injury where glutamate may also be important, are not covered but could become the topic of a second volume or be included in a future edition.

Raimund Buller, MD
Vice President, Global Clinical Research Psychiatry
Lundbeck
37 – 45 Quai du President Roosevelt
F-92445 Issy-les-Moulineaux
France